# Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance

> **NCT06202599** · — · COMPLETED · sponsor: **Peking University People's Hospital** · enrollment: 124 (actual)

## Conditions studied

- Bone Sarcoma
- Soft Tissue Sarcoma
- Refractory Tumor

## Interventions

- **DRUG:** Fruquintinib

## Key facts

- **NCT ID:** NCT06202599
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-25
- **Primary completion:** 2023-08-29
- **Final completion:** 2023-11-15
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2024-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06202599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06202599, "Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06202599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*